AUTL

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Autolus Therapeutics (AUTL – Research Report) today and set a price target of $11.00. The company's shares closed last Friday at $2.37, close to its 52-week low of $2.20. According to TipRanks.com, Burns ' ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -31.7% and a 15.7% success rate. Burns covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Black Diamond Therapeutics, and Springworks Therapeutics. Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $14.00, representing a 469.1% upside.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-autolus-therapeutics-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral